Where next for AstraZeneca stock ahead of Q1 2022 earnings
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
Alexion Pharmaceuticals National Reimbursement Drug List Friday April Volume Based Procurement City Index Demo Trading
Source: cityindex.co.uk